About: Vaccines against Middle East respiratory syndrome coronavirus for humans and camels

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccines against Middle East respiratory syndrome coronavirus for humans and camels Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Vaccines against Middle East respiratory syndrome coronavirus for humans and camels
Creator	Khalaf, Naif Alharbi, Correspondence, N
source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS‐CoV) is caused by a novel betacoronavirus that was isolated in late 2012 in Saudi Arabia. The viral infections have been reported in more than 1700 humans, ranging from asymptomatic or mild cases to severe pneumonia with a mortality rate of 40%. It is well documented now that dromedary camels contract the infection and shed the virus without notable symptoms, and such animals had been infected by at least the early 1980s. The mechanism of camel to human transmission is still not clear, but several primary cases have been associated with camel contact. There is no approved antiviral drug or vaccine against MERS‐CoV despite the active research in this area. Vaccine candidates have been developed using various platforms and regimens and have been tested in several animal models. Here, this article reviews the published studies on MERS‐CoV vaccines with more focus on vaccines tested in large animals, including camels. It is foreseeable that the 1‐health approach could be the best way of tackling the MERS‐CoV endemic in the Arabian Peninsula, by using the mass vaccination of camels in the affected areas to block camel to human transmission. Camel vaccines can be developed in a faster time with fewer regulations and lower costs and could clear this virus from the Arabian Peninsula if accompanied by efficient public health measures.
has issue date	2016-10-27(xsd:dateTime)
bibo:doi	10.1002/rmv.1917
bibo:pmid	27786402
has license	no-cc
sha1sum (hex)	3382972f793a12e7f7a6e1e5d48d4795b3d21f85
schema:url	https://doi.org/10.1002/rmv.1917
resource representing a document's title	Vaccines against Middle East respiratory syndrome coronavirus for humans and camels
has PubMed Central identifier	PMC7169231
has PubMed identifier	27786402
schema:publication	Rev Med Virol
resource representing a document's body	covid:3382972f793a12e7f7a6e1e5d48d4795b3d21f85#body_text
is schema:about of	named entity 'spike protein' named entity 'DDP' named entity 'DPP4' named entity 'protein' named entity 'enzyme' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software